Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)

详细信息    查看全文

• 作者：Ina Zschocke (1)
  Ulrich Mrowietz (2)
  Annett Lotzin (1)
  Eleni Karakasili (1)
  Kristian Reich (3)
  
• 关键词：Topical therapy ; Compliance ; Adherence ; Psoriasis ; Questionnaire ; TTAQ
• 刊名：Archives of Dermatological Research
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：306
• 期：3
• 页码：287-297
• 全文大小：535 KB
• 参考文献：1. Ashcroft DM, Li Wan PA, Williams HC, Griffiths CE (1998) Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 23:391-98 CrossRef
  2. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12 CrossRef
  3. Augustin M, Dieterle W, Zschocke I, Brill C, Trefzer D, Peschen M, Schopf E, Vanscheidt W (1997) Development and validation of a disease-specific questionnaire on the quality of life of patients with chronic venous insufficiency. Vasa 26:291-01
  4. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA (2011) Adherence in the treatment of psoriasis: a systematic review. Dermatology 222:363-74 CrossRef
  5. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I (2004) Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol 14:107-13
  6. Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schafer I, Reusch M, Mielke V, Rustenbach SJ (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res?301:561-71
  7. Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J, Gieler U (2004) German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology 209:14-0 CrossRef
  8. Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D (2009) Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 195:170-77 CrossRef
  9. Bewley A, Page B (2011) Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 25:9-4 CrossRef
  10. Brawley LR, Culos-Reed SN (2000) Studying adherence to therapeutic regimens: overview, theories, recommendations. Control Clin Trials 21:156S-63S CrossRef
  11. Bronsard V, Paul C, Prey S, Puzenat E, Gourraud PA, Aractingi S, Aubin F, Bagot M, Cribier B, Joly P, Jullien D, Le MM, Richard-Lallemand MA, Ortonne JP (2010) What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 24(Suppl 2):17-2 CrossRef
  12. Brown KK, Wingfield ER, Kimball AB (2006) Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 55:607-13 CrossRef
  13. Brown MT, Bussell JK (2011) Medication adherence: WHO cares? Mayo Clin Proc 86:304-14 CrossRef
  14. Bryant LJ (2011) Medicines adherence–evidence for any intervention is disappointing. J Prim Health Care 3:240-43
  15. Butler RJ, Davis TK, Johnson WG, Gardner HH (2011) Effects of nonadherence with prescription drugs among older adults. Am J Manag Care 17:153-60
  16. Dimatteo MR, Giordani PJ, Lepper HS, Croghan TW (2002) Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 40:794-11 CrossRef
  17. Dreno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M (2010) Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol 49:448-56 CrossRef
  18. Epstein RS (2011) Medication adherence: hope for improvement? Mayo Clin Proc 86:268-70 CrossRef
  19. Ersser SJ, Cowdell FC, Latter SM, Healy E (2010) Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol 163:1044-049 CrossRef
  20. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R (2007) Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 57:81-3 CrossRef
  21. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PC (2008) Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 59:1009-016 CrossRef
  22. Finlay AY, Kelly SE (1987) Psoriasis–an index of disability. Clin Exp Dermatol 12:8-1 CrossRef
  23. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)––a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210-16 CrossRef
  24. Flowers B, Wand M, Piltz-Seymour J, Berke SJ, Day D, Teague J, Smoot TM, Landry TA, Bergamini MV, Mallick S (2006) Patients-and physicians-perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension. Clin Ther 28:1803-811 CrossRef
  25. Greenlaw SM, Yentzer BA, O’Neill JL, Balkrishnan R, Feldman SR (2010) Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol 16:253-58 CrossRef
  26. Gupta G, Mallefet P, Kress DW, Sergeant A (2009) Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol 161:221-27 CrossRef
  27. Hodari KT, Nanton JR, Carroll CL, Feldman SR, Balkrishnan R (2006) Adherence in dermatology: a review of the last 20?years. J Dermatol Treat 17:136-42 CrossRef
  28. Hovstadius B, Petersson G (2011) Non-adherence to drug therapy and drug acquisition costs in a national population––a patient-based register study. BMC Health Serv Res 11:326 326 CrossRef
  29. Ingersoll KS, Cohen J (2008) The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 31:213-24 CrossRef
  30. Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE (2009) The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. Pharm World Sci 31:426-31 CrossRef
  31. Kjellgren KI, Ring L, Lindblad A, Maroti M, Serup J (2004) To follow dermatological treatment regimens––patients-and providers-views. Acta Derm Venereol 84:445-50 CrossRef
  32. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB Jr, Balkrishnan R, Feldman SR (2007) Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 56:211-16 CrossRef
  33. Lienert G (1969) Testaufbau und Testanalyse.?Verlag Julius Beltz, Weinheim, Berlin, Basel
  34. Martin LR, Williams SL, Haskard KB, Dimatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1:189-99
  35. Matsui D (2009) Strategies to measure and improve patient adherence in clinical trials. Pharm Med 23:289-97 CrossRef
  36. McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, Van AD (2003) Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 149:323-31 CrossRef
  37. Mokkink LB, Terwee CB, Knol DL, Stratford PW, Alonso J, Patrick DL, Bouter LM, de Vet HC (2006) Protocol of the COSMIN study: COnsensus-based standards for the selection of health measurement INstruments. BMC Med Res Methodol 6:2 CrossRef
  38. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-97 CrossRef
  39. Picardi A, Pasquini P (2007) Toward a biopsychosocial approach to skin diseases. Adv Psychosom Med 28:109-26 CrossRef
  40. Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337-43 CrossRef
  41. Renzi C, Picardi A, Abeni D, Agostini E, Baliva G, Pasquini P, Puddu P, Braga M (2002) Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 138:337-42 CrossRef
  42. Ribera M, Dauden E, Puig L, Briones VG, Herranz JM, Bordas X, Vanaclocha F (2011) Design and validation of a questionnaire to measure treatment satisfaction in patients with moderate-to-severe psoriasis: the NEODERMA study. Actas Dermo-Sifiliográficas 102:28-8
  43. Sabaté E (2003) Adherence to long-term therapies––evidence for action, WHO. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed 16 Jan 2014. WHO1-211
  44. Schmidt J, Lamprecht F, Wittmann WW (1989) Satisfaction with inpatient management. Development of a questionnaire and initial validity studies. Psychother Psychosom Med Psychol 39:248-55
  45. Storm A, Andersen SE, Benfeldt E, Serup J (2008) One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 59:27-3 CrossRef
  46. Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U (2000) Validation and clinical results of the FLQA-d, a quality of life questionnaire for patients with chronic skin diseases. Dermatol Psychosom 1:12-7 CrossRef
  
• 作者单位：Ina Zschocke (1)
  Ulrich Mrowietz (2)
  Annett Lotzin (1)
  Eleni Karakasili (1)
  Kristian Reich (3)
  
  1. SCIderm GmbH, Drehbahn 1-3, 20354, Hamburg, Germany
  2. Department of Dermatology, Psoriasis-Center, University Medical Center Schleswig-Holstein, Schittenhelmstra?e. 7, 24105, Kiel, Germany
  3. Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Germany
  
• ISSN：1432-069X

文摘

Medication adherence rates strongly depend on favorable disease outcomes. It is known that medication adherence rates are lower for topical treatment than for systemic treatment. However, to date no validated instrument for the assessment of adherence factors in topical treatment is available. The aim of this study was to develop a new questionnaire to assess adherence risk factors in topical treatment. The development of the Topical Therapy Adherence Questionnaire (TTAQ) and Patient Preference Questionnaire (PPQ) was based on a systematic literature review, and qualitative patient focus interviews and expert focus groups-input. The psychometric properties and comprehensibility of the TTAQ and PPQ were assessed in a feasibility study with 59 psoriasis patients. Our first preliminary results indicate that the TTAQ and PPQ are psychometrically sound and reliable measures for the assessment of factors influencing topical treatment adherence. The questionnaires are currently being further developed and various parameters (e.g., time point of assessment) are currently being tested in an exploratory pilot study with ca. 2,000 psoriasis patients receiving topical treatment in a European clinical trial. The use of the final versions of TTAQ and PPQ in clinical practice may facilitate the early identification of specific non-adherence factors in patients under topical treatment, which could enable designing and applying adherence-enhancing interventions according to the patient’s individual needs.